Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 40 publications
Zilucoplan-Associated Morpheaform Skin Changes and Methotrexate and UVA1 Phototherapy.
Journal: JAMA dermatology
Published: August 19, 2026
Comprehensive Care Goals in Myasthenia Gravis: Expert Consensus Recommendations Using the RAND/UCLA Appropriateness Method.
Journal: Neurology. Clinical practice
Published: July 09, 2026
An Antibody-Oligonucleotide Conjugate for Myotonic Dystrophy Type 1.
Journal: The New England journal of medicine
Published: February 18, 2026
Impact of patisiran on polyneuropathy of hereditary transthyretin amyloidosis in patients with a V122I or T60A variant: a phase IV multicenter study.
Journal: Annals of medicine
Published: September 20, 2025
Switching to subcutaneous zilucoplan from intravenous complement component 5 inhibitors in generalised myasthenia gravis: a phase IIIb, open-label study.
Journal: Therapeutic advances in neurological disorders
Published: March 04, 2025
Changes in corticosteroid and non-steroidal immunosuppressive therapy with long-term zilucoplan treatment in generalized myasthenia gravis.
Journal: Journal of neurology
Published: February 14, 2025
Improvement of fatigue in generalised myasthenia gravis with zilucoplan.
Journal: Journal of neurology
Published: December 18, 2023
Efficacy and safety of maintenance intravenous immunoglobulin in generalized myasthenia gravis patients with acetylcholine receptor antibodies: A multicenter, double-blind, placebo-controlled trial.
Journal: Muscle & nerve
Published: October 24, 2023
Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study.
Journal: Therapeutic advances in neurological disorders
Published: October 17, 2023
Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.
Journal: The Lancet. Neurology
Published: July 19, 2023
Safety and efficacy of arimoclomol for inclusion body myositis: a multicentre, randomised, double-blind, placebo-controlled trial.
Journal: The Lancet. Neurology
Published: April 01, 2023
Provisional practice recommendation for the management of myopathy in VCP-associated multisystem proteinopathy.
Journal: Annals of clinical and translational neurology
Published: January 19, 2023
Last Updated: 09/26/2026